�Health Discovery Corporation ("HDC") (OTCBB: HDVY) announced that HDC's new gene-based molecular diagnostic test for prostate cancer has now successfully completed it's Phase III double-blind clinical trial and is forthwith ready for commercialization to be used by physicians on their patients at risk of having prostate cancer. The new prostate cancer quiz will be performed at Clarient's Clinical Laboratory in Aliso Viejo, CA. HDC will receive 30% royal family on each test performed.
Results from Phase I, Phase II and Phase III double-blinded clinical validation studies now completed with prostate tissues obtained from multiple sites, including those tested in collaboration with MD Anderson Cancer Center, demonstrated a very heights success pace for identifying the presence of Grade 3 or higher prostate gland cancer cells (clinically significant cancer), as well as, normal and BPH (benign prostatic hyperplasia) cells. To date, 322 prostate tissues have been tested. The combined results of the recently realised double-blinded clinical validation studies demonstrated that the young gene-based molecular diagnostic test for prostate cancer achieved a Sensitivity of 90% for right identifying the presence of Grade 3 or higher prostate cancer cells, and a Specificity of 97% for correctly identifying non-cancer cells (normal and BPH), representing an overall try accuracy of 93%.
"We are selfsame pleased with the net results of the double blind clinical trial and are excited to have our first tax income producing molecular diagnostic test ready for commercialization," declared Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "The successful ontogeny, validation and commercialization of this new molecular symptomatic test for prostate malignant neoplastic disease proves that HDC, by combining our patented SVM and SVM-RFE technology and our expert Scientific Team, has the ability to produce new molecular symptomatic and portent tests which are the future of personalized medicine. Our patent protected discovery method allows us to develop molecular diagnostic and prognostic tests that are free of outside intellectual property rights and thereby allows HDC to fully patent protect our molecular diagnostic factor signatures. Using the same expertise of our Scientific Team and the HDC patented engineering, we are currently development additional unexampled molecular symptomatic tests in a variety of other cancers some of which we hope will be commercially uncommitted in Q4 of 2008."
Dr. Barnhill continued "We are proud of to take in HDC's new gene-based prostate cancer quiz enter the market like similar molecular diagnostic tests based on unique cistron expression profiles such as OncotypeDX from Genomic Health, Inc. (NasdaqGM:GHDX) and MammaPrint from Agendia."
In the United States alone thither are over 1 1000000 prostate genus Cancer tissue biopsy procedures performed annually. Approximately 25% of these tissue biopsies ar reported "cocksure" indicating the presence of prostate crab. The other 75% of prostate cancer tissue biopsies are reported as "negative" for the presence of cancer. However, one-third of the workforce with initial prostate cancer tissue biopsies that are reported as "negative" for prostate crab (roughly 25% of men at risk of having prostate crab) actually do have prostate cancer that was lost by the first biopsy (False Negative). These men actually have prostate cancer that was missed by the initial tissue biopsy for a variety of reasons. Health Discovery Corporation's prostate cancer molecular diagnostic test is a genomics based test that should be performed on the 75% of men (about 600,000 men each year in the US unequaled) with initial biopsies reported as negative to attend physicians in identifying those men world Health Organization could get prostate cancer that was missed by the low biopsy.
"The excellent results seen in Phase I, Phase II, and Phase III double-blinded clinical trials validate the scientific truth and robustness of the HDC gene-based molecular symptomatic test for prostate cancer," stated Dr. Herbert Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. "Physicians that ar diagnosing and treating prostate gland cancer patients will be greatly assisted by the additional information that this new prostate cancer quiz will add together to their decision devising process."
In a Press Release issued yesterday, Ron Andrews, CEO of Clarient stated "We are selfsame impressed with the results from these validation studies, and I applaud the development teams from both Clarient and HDC for their persevering efforts in bringing this new test through the validation phase angle significantly ahead of schedule. The early results from these studies confirm our belief that this potent genomics-based test may leave physicians with useful information to assure that men with prostate cancer catch a more accurate diagnosis sooner and minimize the need for unnecessary biopsies."
HDC plans to straight off begin presenting papers for publication and presentations at upcoming meetings as we initiate the marketing phase of commercialization. Because of the clinical trial success of this prostate malignant neoplastic disease test, the company plans to lead up a subject area utilizing piss samples to potentially enlarge the indication of this new prostate gland cancer test to be used as a screening tool, which could significantly expand the current market opportunity to include all men at risk for prostate cancer.
About Health Discovery Corporation
Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the force field of rule recognition engineering. Through the application of its patent protected engineering science, HDC is a leader in SVM-based molecular symptomatic and prodigy test evolution in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM radiation pattern recognition tools have significant application potential difference in other sizable commercial markets such as oil exploration, fiscal markets, Internet search and spam, native land security, and other areas where analysis of large volumes of complex information is requisite.
This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can fall in no assurance that such expectations will prove correct.
Health Discovery Corporation
More info
